Health Care · Pharmaceutical Preparations

EOLS Evolus, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 157056276 filings
Russell 2000

EOLS at a glance

Evolus, Inc. (EOLS, SEC CIK 1570562) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as September 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Evolus, Inc. (EOLS) reported revenue of $297.2 million (up 11.6% from FY2024) and a net loss of $51.6 million. Diluted EPS was -$0.80.
  • As of September 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Evolus, Inc. (EOLS) shares worth $126.8 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by MOATAZEDI DAVID on September 2, 2026 of 105,108 shares at $9.04 per share.
  • In the last 90 days, EOLS insiders reported 0 open-market purchases ($0) and 1 open-market sale ($950K) on Form 4, a net sale of $950K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$297.2M
+11.6% vs prior year
Insiders · 90 days
0 buys · 1 sell
Net −$950K
13F holders
23 funds
$126.8M · +0 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New tariff risk triggered by 2026 Section 232 action: South Korean Jeuveau imports currently face 15% tariffs, with potential rates up to 100%
  • Regulatory risk from Section 232 medical-device investigation: future tariffs, quotas, or import restrictions could affect France-sourced Evolysse
  • Competitive risk: AbbVie and Galderma retain larger market shares, sales forces, portfolios, and discounting capacity
  • Financial risk: $31.2 million nine-month net loss and $692.3 million accumulated deficit increase reliance on future financing
  • Supply risk: sole reliance on Daewoong and Symatese leaves Jeuveau and Evolysse vulnerable to manufacturing disruptions

Management Discussion & Analysis

  • Q3 revenue $78.0M, up 13.0% from $69.0M, driven by higher Jeuveau and Evolysse sales
  • Gross margin 65.0% vs 66.5% YoY, operating loss $8.4M vs $11.5M
  • One reportable segment, Jeuveau and Evolysse; both products cited as revenue-growth drivers
  • Cash $41.7M, operating cash use $15.5M through nine months vs $55.1M YoY
  • Outlook: growth dependent on Evolysse launches and U.S. approvals, with tariff and discretionary-spending headwinds

AI summary of the EOLS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Evolus announced financial results for the quarter ended September 30, 2026
  • Detailed results and management commentary are contained in Exhibit 99.1 accompanying the 8-K

Item EX-99.1: Item EX-99.1

  • Q3 revenue $78.0M, up 13% YoY, led by $70.1M toxin revenue and $7.9M HA gel revenue
  • Adjusted EBITDA $1.2M versus $(3.1)M, marking the fourth consecutive positive quarter despite GAAP operating loss of $8.4M
Filed Aug 5, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 revenue $84.1M, up 21%, with toxin revenue $75.2M and HA gel revenue $8.9M
  • Adjusted EBITDA $4.7M versus $(7.9)M, marking the third consecutive positive quarter and $12.6M improvement

Item 2.02: Results of Operations and Financial Condition

  • Press release covers Evolus financial results for quarter ended June 30, 2026
  • Investor-relevant revenue, earnings and outlook details are contained in Exhibit 99.1
Filed Aug 4, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • Exclusive Estyme injectable gel rights added in Canada, Australia and New Zealand
  • €920,000 upfront payment plus up to €1.38 million tied to regulatory approvals

Item EX-99.1: Item EX-99.1

  • Exclusive Estyme rights expanded to Canada, Australia, and New Zealand, completing Evolus’ injectable portfolio coverage across existing commercial markets
  • Addressable neurotoxin and dermal filler market approximately $500 million annually, with 60% neurotoxins and 40% dermal fillers

Item 7.01: Regulation FD Disclosure

  • Press release announces execution of an Amendment, signaling a potentially material change to an existing company agreement
  • Exhibit 99.1 contains the Amendment’s substantive terms and investor-relevant details

AI summaries of EOLS 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for EOLS

Don't miss the next EOLS filing

  • Alerts as it files. A push when EOLS files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut EOLS, by share count.
  • Ask anything. An AI agent that reads every EOLS filing and answers with sources.

EOLS alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
MOATAZEDI DAVIDSellSep 2, 2026$9.04
MOATAZEDI DAVIDSellMar 20, 2026$4.75
Avelar RuiSellMar 20, 2026$4.75
Avelar RuiSellMar 17, 2026$4.89
MOATAZEDI DAVIDSellMar 17, 2026$4.89
Avelar RuiMMar 16, 2026-
Avelar RuiMMar 16, 2026-
MOATAZEDI DAVIDMMar 16, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$266.3M$297.2M
Gross Profit-$182.3M$197.1M
Operating Income--$34.4M-$32.7M
Net Income--$50.4M-$51.6M
Gross Margin-68.5%66.3%
Op. Margin--12.9%-11.0%
Net Margin--18.9%-17.4%
Balance Sheet
Total Assets-$232.6M$225.9M
Equity-$20.7M$5.5M-$23.1M
ROE--913.1%223.5%
Per Share
EPS-$-0.81$-0.80
Cash Flow
Operating CF--$18.0M-$42.3M
CapEx$473K$1.5M$3.4M

Source: XBRL data in Evolus, Inc. (EOLS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate EOLS share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
EOLS shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202623$126.8M
Q2 202623$104.4M
Q1 202622$57.6M
Q4 202524$117.1M
Q3 202523$103.4M
Q2 202523$145.4M
Q1 202523$140.2M
Q4 202418$101.9M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 179 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

EOLS filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 4, 2026Analysis
8-KNov 4, 2026Analysis-
4Sep 4, 2026--
SC 13GAug 31, 2026-
10-QAug 5, 2026Analysis
8-KAug 5, 2026Analysis-
8-KAug 4, 2026Analysis-
8-KJul 8, 2026Analysis-
8-KJun 12, 2026Analysis-
10-QMay 4, 2026Analysis
8-KMay 4, 2026Analysis-
4Mar 20, 2026--
4Mar 20, 2026--
4Mar 18, 2026--
4Mar 18, 2026--
8-KMar 13, 2026Analysis-
10-KMar 3, 2026-
8-KMar 3, 2026Analysis-
4Feb 19, 2026-
4Feb 19, 2026-
4Feb 19, 2026-
4Feb 19, 2026-
8-KJan 9, 2026-
4Dec 29, 2025-
4Dec 29, 2025-

Related Health Care companies

All Health Care →

EOLS SEC filings: frequently asked questions

Are EOLS insiders buying or selling?

In the last 90 days, Evolus, Inc. (EOLS) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $950,019 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold EOLS stock?

As of September 30, 2026, the largest Evolus, Inc. (EOLS) holders among the 13F filers tracked by SignalX were BlackRock ($42.5 million), Vanguard Capital Management LLC ($18.1 million), State Street Corp ($14.8 million), Millennium Management ($13.2 million), Goldman Sachs Group ($10.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was EOLS's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Evolus, Inc. (EOLS) reported revenue of $297.2 million (up 11.6% from FY2024) and a net loss of $51.6 million. Diluted EPS was -$0.80. The figures come from the XBRL data in the 10-K.

What did EOLS report in its latest 8-K?

Evolus, Inc. (EOLS) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Evolus announced financial results for the quarter ended September 30, 2026.

What are the latest EOLS SEC filings?

Evolus, Inc. (EOLS) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on September 4, 2026.

What is EOLS's SEC CIK number?

Evolus, Inc. (EOLS)'s SEC Central Index Key (CIK) is 1570562. EDGAR lists every EOLS filing under that number.

Ask anything about EOLS

The research agent reads EOLS's filings, financials, insider trades and 13F holders, then answers with sources.